

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**022407Orig1s000**

**PROPRIETARY NAME REVIEW(S)**

*Cross referenced to NDA 22-110*



**Department of Health and Human Services  
Public Health Service  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Surveillance and Epidemiology**

Date: August 7, 2009

To: Wiley Chambers, MD, Acting Director  
Division of Anti-Infective and Ophthalmology Products

Through: Denise Toyer, Pharm.D., Deputy Director  
Carol Holquist, RPh, Director  
Division of Medication Error Prevention and Analysis (DMEPA)

From: Kristina C. Arnwine, PharmD, Team Leader  
Division of Medication Error Prevention and Analysis (DMEPA)

Subject: Proprietary Name Review

Drug Name(s): Vibativ (Telavancin) for Injection, 250 mg and 750 mg

Application Type/Number: NDA 22-110

Applicant/Applicant: Theravance, Inc.

OSE RCM #: 2009-644

**\*\*\* This document contains proprietary and confidential information that should not be released to the public.\*\*\***

The content of this review can be found at  
Drugs@FDA in the Name Review for 022110

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

KRISTINA C ARNWINE  
08/07/2009

DENISE P TOYER  
08/07/2009

CAROL A HOLQUIST  
08/07/2009